Jessamy Tiffen
#104,182
Most Influential Person Now
Australian scientist
Jessamy Tiffen's AcademicInfluence.com Rankings
Jessamy Tiffenchemistry Degrees
Chemistry
#5917
World Rank
#7185
Historical Rank
Physical Chemistry
#965
World Rank
#1039
Historical Rank

Download Badge
Chemistry
Why Is Jessamy Tiffen Influential?
(Suggest an Edit or Addition)According to Wikipedia, Dr. Jessamy Tiffen is an Australian Scientist and senior researcher in the Melanoma Immunology and Oncology Program at the Centenary Institute of Cancer Medicine and Cell Biology at the University of Sydney, New South Wales, Australia. Her work primarily focuses on fundamental cell biology, examining the transformation of normal cells into cancerous ones and their responses to different treatments.
Jessamy Tiffen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- POT1 loss-of-function variants predispose to familial melanoma (2014) (318)
- Targeting glutamine transport to suppress melanoma cell growth (2014) (188)
- Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB (2015) (178)
- Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. (2013) (156)
- Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. (2011) (152)
- Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. (2019) (128)
- Inactivating CUX1 mutations promote tumorigenesis (2013) (111)
- Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo (2010) (89)
- Control of NF‐kB activity in human melanoma by bromodomain and extra‐terminal protein inhibitor I‐BET151 (2014) (76)
- Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling (2015) (72)
- Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes (2015) (69)
- Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma (2018) (56)
- The cancer‐testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells (2013) (50)
- HDAC inhibitors restore BRAF‐inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma (2018) (43)
- EZH2: an emerging role in melanoma biology and strategies for targeted therapy (2015) (41)
- Adenoma development in familial adenomatous polyposis and MUTYH‐associated polyposis: somatic landscape and driver genes (2015) (41)
- Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma (2016) (41)
- Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy (2015) (36)
- EZH2 cooperates with DNA methylation to downregulate key tumour suppressors and interferon gene signatures in melanoma. (2020) (34)
- EZH2 as a mediator of treatment resistance in melanoma (2016) (26)
- Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients (2020) (14)
- Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells (2015) (12)
- Study of the Female Sex Survival Advantage in Melanoma—A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts (2020) (12)
- Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma (2020) (11)
- Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma? (2020) (9)
- Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers (2021) (8)
- A combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma. (2021) (5)
- Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma. (2021) (5)
- Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells (2022) (3)
- Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma (2021) (3)
- Sex bias of females in survival from cancer and infections. Is X the answer? (2021) (3)
- EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma (2020) (2)
- Shedding light on dabrafenib-induced fevers in patients with melanoma. (2019) (1)
- Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7 (2022) (1)
- Abstract 1676: EZH2 inhibitors in immunotherapy of melanoma (2017) (1)
- Molecular and Cellular Pathobiology Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression (2011) (1)
- Somatic copy number amplification and activating somatic mutations of EZH2 Y641 drive melanoma by epigenetic remodeling. (2015) (1)
- Mesenchymal Stem Cells as Suicide Gene Therapy Vehicles for Organ-Confined and Metastatic Prostate Cancer (PCa). (2007) (1)
- Combining BET and HDAC inhibitors to potentiate their effectiveness against melanoma and to suppress AKT and YAP signaling. (2015) (1)
- Abstract 1384: The epigenetic modifier EZH2 represses antitumor immunity in melanoma (2018) (0)
- 700 BORIS and its paralogue CTCF exhibit similar biological functions (2010) (0)
- POT1 mutations predispose to familial melanoma (2013) (0)
- Abstract 5190: EZH2 epigenetically silences anti-tumor immunity in melanoma via dual histone and DNA methylation (2019) (0)
- Abstract 5149: EZH2 as a novel therapeutic target in melanoma treatment (2014) (0)
- Androgen receptor and nutrient signaling pathways coordinate increased amino acid transport in prostate cancer progression (2012) (0)
- Abstract 826: Global DNA methylation levels regulate PD-L1 expression in melanoma (2019) (0)
- Abstract 2947: Regulation of PD-L1 expression in human melanoma by NF-kB (2014) (0)
- Overexpression of VIRMA Confers Vulnerability to Breast Cancers via the m 6A-Dependent Regulation of Unfolded Protein Response (2022) (0)
- Supplementary information Inactivating CUX1 mutations promote tumorigenesis (2013) (0)
- Abstract LB-177: BET and CDK9 protein inhibitors: Novel epigenetic therapy to synergistically kill human melanoma cells (2020) (0)
- Abstract 20: POT1 mutations predispose to familial melanoma (2014) (0)
This paper list is powered by the following services:
Other Resources About Jessamy Tiffen
What Schools Are Affiliated With Jessamy Tiffen?
Jessamy Tiffen is affiliated with the following schools: